Teva's long-lasting schizophrenia injectable shines in Phase III

By Yahoo! Finance | Nov 4, 2024 at 12:27 PM EST

Teva Pharmaceuticals' TEV-479 (olanzapine) showed significant improvements in schizophrenia symptoms and quality of life in a Phase III trial. The study revealed positive results across different doses, outperforming the placebo, with potential benefits for patient adherence and management of schizophrenia.

Did you find this insightful?

Bad

Just Okay

Amazing

We are preparing, please wait

New Alert

Select an alert type

Sentiment Spike

Send email alert if news sentiment changes significantly

Mentions Spike

Send email alert if has a surge in mentions

Choose sentiment spike or mentions spike or both to receive email alerts and app notification for the selected stock.
Note: Please be aware that you will receive an email only once a day, around 8:00 AM (EST), in the event of any spike.
In future if you don't want to receive any email then delete stocks added into alert section.